The FDA Debarment List is a public list of individuals and firms that the U.S. Food and Drug Administration has barred from participating in certain drug-related activities.
It exists under Section 306 of the Federal Food, Drug, and Cosmetic Act, added by the Generic Drug Enforcement Act of 1992, and it identifies parties prohibited from working on or submitting drug product applications.
The list was created after the generic drug scandals of the late 1980s, with the stated purpose of restoring integrity to the drug approval process.
It is often confused with the OIG exclusion list, but the two are separate. They cover different conduct, come from different agencies, and carry different consequences.
What does FDA debarment actually prohibit?
Debarment is a bar on participation, and what it bars depends on whether the debarred party is an individual or a firm.
A debarred individual cannot provide services in any capacity to a company that has an approved or pending drug product application. A debarred firm or entity cannot submit or assist in submitting drug applications, and the statute also reaches certain food import activities.
There is a second obligation that catches many organizations off guard. Under the law, anyone submitting a drug application must certify that they did not and will not use the services of a debarred person in connection with that application. That makes checking the list a routine compliance step for drug applicants, not an occasional one.
Mandatory vs. permissive debarment
The FD&C Act splits debarment into two categories, and the distinction determines both who gets debarred and for how long.
Mandatory debarment applies to individuals convicted of a felony relating to the development, approval, or regulation of a drug product. These periods run from one to ten years, and certain felonies carry permanent debarment.
Permissive debarment covers a broader set of conduct, such as misdemeanors or felonies not directly tied to drug regulation, and is generally limited to five years for individuals.
In either case, the FDA issues a notice and an opportunity for a hearing, then publishes a final debarment order in the Federal Register. The agency maintains the list publicly and updates it as new orders are issued, alongside a separate list of debarments that have expired.
A debarred individual cannot provide services in any capacity to a company that has an approved or pending drug product application.
FDA debarment vs. OIG exclusion
FDA debarment comes from the Federal Food, Drug, and Cosmetic Act and bars a party from drug application and approval activities. The OIG exclusion list, by contrast, comes from the Social Security Act and bars a party from federally funded healthcare programs such as Medicare and Medicaid.
Different agencies, different statutes, different scope. A person can appear on one list and not the other, which is exactly why a screening program built only around healthcare program exclusions can miss a debarment entirely.
Why the FDA debarment list matters
The consequences of getting this wrong fall on the organization, not just the debarred individual.
Using the services of a debarred person, or providing services while debarred, can trigger civil penalties that reach into the hundreds of thousands of dollars. Beyond the fines, an inaccurate debarment certification can jeopardize a pending drug approval and invite broader enforcement.
This makes the list most relevant to pharmaceutical companies, generic drug manufacturers, drug sponsors, and contract manufacturers, along with any organization whose work touches drug product applications.
Where the FDA debarment list fits into screening
For most healthcare providers, the OIG exclusion list, the SAM exclusion list, and state Medicaid lists are the core of a screening program. The FDA debarment list sits alongside them as one more federal source that a complete program accounts for.
Organizations running a thorough sanctions screening process, particularly those involved in drug products, fold the debarment list into the same workflow as their other exclusion screening checks.Â
The principle is the same one that applies across sanctions work: coverage. A risk that appears on one list and not another is only caught if every applicable list is checked.
How Streamline Verify supports comprehensive screening
Few organizations have the capacity to track each federal and state list by hand, on a recurring basis, against a full roster of people and vendors. That is where coverage gaps form.
Platforms like Streamline Verify screen against the OIG LEIE, the SAM exclusion list, state Medicaid lists, and additional federal sources, matching name variations and identifiers so potential matches are not missed. The platform continues ongoing exclusion monitoring over time and records each check in a time-stamped audit trail.
By keeping screening comprehensive across the lists that apply to an organization, Streamline Verify helps compliance teams avoid the blind spots that come from checking only part of the picture.
Want to see how the FDA debarment list fits into your screening program?
